| Topoisomerase I inhibitors: camptothecins and beyond Y Pommier Nature Reviews Cancer 6 (10), 789-802, 2006 | 2432 | 2006 |
| DNA topoisomerases and their poisoning by anticancer and antibacterial drugs Y Pommier, E Leo, HL Zhang, C Marchand Chemistry & biology 17 (5), 421-433, 2010 | 2183 | 2010 |
| Trapping of PARP1 and PARP2 by clinical PARP inhibitors J Murai, SYN Huang, BB Das, A Renaud, Y Zhang, JH Doroshow, J Ji, ... Cancer research 72 (21), 5588-5599, 2012 | 2083 | 2012 |
| A gene expression database for the molecular pharmacology of cancer U Scherf, DT Ross, M Waltham, LH Smith, JK Lee, L Tanabe, KW Kohn, ... Nature genetics 24 (3), 236-244, 2000 | 1849 | 2000 |
| γH2AX and cancer WM Bonner, CE Redon, JS Dickey, AJ Nakamura, OA Sedelnikova, ... Nature Reviews Cancer 8 (12), 957-967, 2008 | 1794 | 2008 |
| Integrase inhibitors to treat HIV/AIDS Y Pommier, AA Johnson, C Marchand Nature reviews Drug discovery 4 (3), 236-248, 2005 | 988 | 2005 |
| Drugging topoisomerases: lessons and challenges Y Pommier ACS chemical biology 8 (1), 82-95, 2013 | 900 | 2013 |
| Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139 EP Rogakou, W Nieves-Neira, C Boon, Y Pommier, WM Bonner Journal of Biological Chemistry 275 (13), 9390-9395, 2000 | 878 | 2000 |
| Roles of eukaryotic topoisomerases in transcription, replication and genomic stability Y Pommier, Y Sun, SN Huang, JL Nitiss Nature reviews Molecular cell biology 17 (11), 703-721, 2016 | 846 | 2016 |
| Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib J Murai, SYN Huang, A Renaud, Y Zhang, J Ji, S Takeda, J Morris, ... Molecular cancer therapeutics 13 (2), 433-443, 2014 | 791 | 2014 |
| Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme Y Pommier, P Pourquier, YI Fan, D Strumberg Biochimica et Biophysica Acta (BBA)-Gene Structure and Expression 1400 (1-3 …, 1998 | 791 | 1998 |
| DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition Y Pommier Chemical reviews 109 (7), 2894-2902, 2009 | 779 | 2009 |
| CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set WC Reinhold, M Sunshine, H Liu, S Varma, KW Kohn, J Morris, ... Cancer research 72 (14), 3499-3511, 2012 | 766 | 2012 |
| Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks Y Pommier, O Sordet, S Antony, RL Hayward, KW Kohn Oncogene 23 (16), 2934-2949, 2004 | 743 | 2004 |
| Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity C Jaxel, KW Kohn, MC Wani, ME Wall, Y Pommier Cancer research 49 (6), 1465-1469, 1989 | 680 | 1989 |
| Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action Y Pommier, MJ O’Connor, J De Bono Science translational medicine 8 (362), 362ps17-362ps17, 2016 | 653 | 2016 |
| Induction of a common pathway of apoptosis by staurosporine R Bertrand, E Solary, P O'Connor, KW Kohn, Y Pommier Experimental cell research 211 (2), 314-321, 1994 | 644 | 1994 |
| Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA MS Kim, M Blake, JH Baek, G Kohlhagen, Y Pommier, F Carrier Cancer research 63 (21), 7291-7300, 2003 | 619 | 2003 |
| Topoisomerase I suppresses genomic instability by preventing interference between replication and transcription S Tuduri, L Crabbé, C Conti, H Tourrière, H Holtgreve-Grez, A Jauch, ... Nature cell biology 11 (11), 1315-1324, 2009 | 610 | 2009 |
| Structures of three classes of anticancer agents bound to the human topoisomerase I− DNA covalent complex BL Staker, MD Feese, M Cushman, Y Pommier, D Zembower, L Stewart, ... Journal of medicinal chemistry 48 (7), 2336-2345, 2005 | 581 | 2005 |
